Global Nonstructural Protein 4B (NS4B) Pipeline Review, H1 2016 - Gilead Sciences, GSK, Inovio, Johnson & Johnson & Merck & Co - Research and Markets

 This report provides comprehensive information on the therapeutic development for Nonstructural Protein 4B NS4B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nonstructural Protein 4B NS4B and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

    Introduction
    Nonstructural Protein 4B NS4B Overview
    Therapeutics Development
    Pipeline Products for Nonstructural Protein 4B NS4B - Overview
    Pipeline Products for Nonstructural Protein 4B NS4B - Comparative Analysis
    Nonstructural Protein 4B NS4B - Therapeutics under Development by Companies
    Nonstructural Protein 4B NS4B - Therapeutics under Investigation by Universities/Institutes
    Nonstructural Protein 4B NS4B Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Nonstructural Protein 4B NS4B - Products under Development by Companies
    Nonstructural Protein 4B NS4B - Products under Investigation by Universities/Institutes
    Nonstructural Protein 4B NS4B - Companies Involved in Therapeutics Development